For the quarter ending 2024-06-30, MEDS made $18,699 in revenue. -$1,833,902 in net income. Net profit margin of -9807.49%.
| Income Statement | 2024-06-30 | |||
|---|---|---|---|---|
| Revenue | 18,699 | |||
| Cost of sales | 19,402 | |||
| Gross profit | -703 | |||
| General and administrative | 415,421 | |||
| Technology expense | 86,674 | |||
| Accounting and legal expense | 171,708 | |||
| Professional fees | 509,136 | |||
| Wage and salary expense | 312,049 | |||
| Operating expenses | 1,494,988 | |||
| Operating income (loss) | -1,495,691 | |||
| Interest expense, nonoperating | 4,949 | |||
| Interest income | 41,031 | |||
| Change in fair value of warrant liability | -165,132 | |||
| Nonoperating income (expense) | -129,050 | |||
| Net loss from continuing operations | -1,624,741 | |||
| Net (loss) income on discontinued operations | -209,161 | |||
| Net income (loss) | -1,833,902 | |||
| Basic eps | -1.3 | |||
| Diluted eps | -1.3 | |||
| Basic average shares | 1,406,348 | |||
| Diluted average shares | 1,406,348 | |||
null (MEDS)
null (MEDS)